Literature DB >> 11792716

BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis.

Peter A Edwards1, Heidi R Kast, Andrew M Anisfeld.   

Abstract

During the last three years there have been a plethora of publications on the liver X-activated receptors (LXRalpha, NR1H3, and LXRbeta, NR1H2), the farnesoid X-activated receptor (FXR, NR1H4), and the pregnane X receptor (PXR, NR1I2) and the role these nuclear receptors play in controlling cholesterol, bile acid, lipoprotein and drug metabolism. The current interest in these nuclear receptors is high, in part, because they appear to be promising therapeutic targets for new drugs that have the potential to control lipid homeostasis. In this review we emphasize i) the role of LXR in controlling many aspects of cholesterol and fatty acid metabolism, ii) the expanded role of FXR in regulating genes that control not only bile acid metabolism but also lipoprotein metabolism, and iii) the regulation of bile acid transport/metabolism in response to bile acid-activated PXR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792716

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  100 in total

1.  Identification of macrophage liver X receptors as inhibitors of atherosclerosis.

Authors:  Rajendra K Tangirala; Eric D Bischoff; Sean B Joseph; Brandee L Wagner; Robert Walczak; Bryan A Laffitte; Chris L Daige; Diane Thomas; Richard A Heyman; David J Mangelsdorf; Xuping Wang; Aldons J Lusis; Peter Tontonoz; Ira G Schulman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-22       Impact factor: 11.205

Review 2.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

3.  Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis.

Authors:  P T Clayton; A Verrips; E Sistermans; A Mann; G Mieli-Vergani; R Wevers
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

Review 4.  Squalene synthase inhibitors.

Authors:  V C Menys; P N Durrington
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 5.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro.

Authors:  Deanna L Howarth; Lee R Hagey; Sheran H W Law; Ni Ai; Matthew D Krasowski; Sean Ekins; John T Moore; Erin M Kollitz; David E Hinton; Seth W Kullman
Journal:  Aquat Toxicol       Date:  2010-03-01       Impact factor: 4.964

7.  Inhibitory effects of bile acids and synthetic farnesoid X receptor agonists on rotavirus replication.

Authors:  Yunjeong Kim; Kyeong-Ok Chang
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

8.  Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.

Authors:  Johannes Schmitt; Bo Kong; Grace L Guo; Andreas Geier; Bruno Stieger; Oliver Tschopp; Simon M Schultze; Monika Rau; Achim Weber; Beat Müllhaupt
Journal:  Liver Int       Date:  2014-02-07       Impact factor: 5.828

9.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes.

Authors:  Jay D Horton; Nila A Shah; Janet A Warrington; Norma N Anderson; Sahng Wook Park; Michael S Brown; Joseph L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

10.  Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy.

Authors:  H A Lemonde; E J Custard; J Bouquet; M Duran; H Overmars; P J Scambler; P T Clayton
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.